Current Research Studies

Cancer – NANT 2011-01: Study of Single-Agent 131I-MIBG with Vincristine and Irinotecan, or 131I-MIBG with Vorinostat for Resistant/Relapsed Neuroblastoma

Condition or Therapy:



Cancer and blood disorders

What is the goal of this study?

The goal of this study is to compare three different treatments that all contain metaiodobenzylguanidine (MIBG) to compare which has the best response to people diagnosed with relapsed or persistent neuroblastoma.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are between 2 and 30 years old and
  • Have relapsed or refractory neuroblastoma

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Julie Park